CN101884730B - Chinese medicinal preparation for treating hypoproteinemia caused by liver damage - Google Patents

Chinese medicinal preparation for treating hypoproteinemia caused by liver damage Download PDF

Info

Publication number
CN101884730B
CN101884730B CN2010101787035A CN201010178703A CN101884730B CN 101884730 B CN101884730 B CN 101884730B CN 2010101787035 A CN2010101787035 A CN 2010101787035A CN 201010178703 A CN201010178703 A CN 201010178703A CN 101884730 B CN101884730 B CN 101884730B
Authority
CN
China
Prior art keywords
radix
parts
rhizoma
group
thick paste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101787035A
Other languages
Chinese (zh)
Other versions
CN101884730A (en
Inventor
睢大筼
许磊
陈燕萍
许恩伯
于晓风
曲绍春
王志才
马兴元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin University
Original Assignee
Jilin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin University filed Critical Jilin University
Priority to CN2010101787035A priority Critical patent/CN101884730B/en
Publication of CN101884730A publication Critical patent/CN101884730A/en
Application granted granted Critical
Publication of CN101884730B publication Critical patent/CN101884730B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a Chinese medicinal preparation for treating hypoproteinemia caused by liver damage, which is prepared from panax ginseng, siberian solomonseal rhizome, rehmanniae praeparatum, Chinese angelica, figwort root, tortoise-shell glue, szechuan lovage rhizome, large-headed atractylodes rhizome, Chinese thorowax root and the like. The Chinese medicinal preparation has the effects of soothing the liver and tonifying the spleen, invigorating blood circulation and removing blood stasis, softening hard lumps and dispelling nodes and nourishing vital qi, can eliminate ascites and improve plasma albumin obviously on patients who suffer from cirrhosis ascites with low albumin so as to regulate the viscera function of bodies integrally without attending to one thing and losing another, and has the advantages of long-term administration and no toxic or side effect.

Description

A kind of treatment is because the Chinese medicine preparation of the hypoproteinemia card that hepar damnification caused
Technical field
The present invention discloses a kind of treatment because the Chinese medicine preparation of the hypoproteinemia card that hepar damnification caused belongs to traditional Chinese medical science pharmaceutical technology field.
Background technology:
Present stage treatment all is to be main with the intravenous injection human albumin by the hypoproteinemia that hepatic injury caused usually.But obviously shortage of the regular human albumin's injection in domestic market at present costs an arm and a leg, and the interior time of staying of body is shorter, and certain application limitation is arranged.Symptom is more serious, as: produce the symptom that edema appears in ascites and lower limb, how to impel the urine amount to increase, alleviate the situation of water retention with diuretic.Though respite, the permanent use can produce more serious Drug resistance, and be serious, can cause at last can't reaching the diuretic effect after the administration.If the ascites volume super large is for mitigate the disease generally all can carry out the medical procedure that ascites extracts and extracts re-injection.But well-known, this way can't fundamentally solve abdominal cavity water hydrorrhea and go out, and ascites is taken out more sliding and more sliding, and is serious, can cause the serious decline of physical function and many complication to produce.
Present clinical correction hypoalbuminemia mainly adopts intravenous drip or intravenous injection human albumin treatment, and Shang Weijian can liver function protecting, reverses hepatic fibrosis, can correct the medicine of the low treating both the principal and secondary aspects of a disease of cirrhotic ascites companion plasma albumin again.
Summary of the invention:
A kind of treatment is provided in the present invention because the Chinese medicine preparation of the hypoproteinemia card that hepar damnification caused has solved the hypoproteinemia that the hepatic injury patient causes.
The present invention adopts following solution: with the theory of Chinese medical science is guidance, focuses on to improve patient's autoimmune function, conditioning viscera fortuneization function; Multi-faceted treatment not only improves liver function, and payes attention to strengthening the maintenance adjustment of physical function; Treating both the principal and secondary aspects of a disease; With just anti-evil, thereby realize not only treating the internal organs disease but also setting upright physical function, make it the medical effect of integral rehabilitation.
Treatment of the present invention is because the Chinese medicine preparation of hypoproteinemia that hepar damnification caused card, mainly by following parts by weight of raw materials process (be called for short: preparation A):
5～30 parts of Radix Ginsengs, 5～30 parts of Rhizoma Polygonatis, 5～30 parts in the Radix Rehmanniae, 5～30 parts of Radix Angelicae Sinensis, 5～30 parts of Radix Scrophulariaes, 5～30 parts of Colla Plastri Testudinises, 5～30 parts of Rhizoma Chuanxiongs, 5～30 parts of the Rhizoma Atractylodis Macrocephalaes, 5～30 parts of Radix Bupleuri.
Concrete method for preparing is following:
1. get Rhizoma Chuanxiong, Radix Angelicae Sinensis pulverizing, both are mixed, soak 1-6h, vapor distillation, heating extraction 5-15h, extraction, it is subsequent use to get volatile oil; Aqueous solution and preceding twice water cooking liquid 3. merge, and residue joins in second residue 3. and merges.
2. get Radix Bupleuri, Radix Scrophulariae and pulverize, with the ethanol extraction of 50%-90% 2-4 time, be 0.5-3h at every turn, merging filtrate, and recovery ethanol, concentrated, doubly measure 95% ethanol precipitation with 2-5; Filter, residue discards, and filtrating is recycled to the thick paste shape, and dries in the baking oven, grinds.
3. get Radix Ginseng, the Radix Rehmanniae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae and pulverize, add water 5-12 and doubly measure and boil 2-4 time, each 0.5-3h merges, and filters, concentrated thick paste shape.
4. get Colla Plastri Testudinis and pulverize, cross 80 mesh sieves.
5. with the above-mentioned thick paste that obtains, powder and Colla Plastri Testudinis powder fully mix, and dry in the baking oven, take out, and add the above-mentioned volatile oil that obtains, mixing.
6. process required preparation type by preparation process, like powder, capsule, pill etc.
The present invention can also be by raw material in the above-mentioned prescription and following portions by weight proportion raw material process (be called for short: preparation B):
5～30 parts in Cornu Cervi Pantotrichum, 5～30 parts of Radix Paeoniae Rubra, 5～30 parts in Radix Glycyrrhizae, 5～30 parts of Rhizoma Cyperis.
Method for preparing is following:
1. get Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Cyperi pulverizing, the three is mixed, soak 1-6h, vapor distillation, heating extraction 5-15h, extraction, it is subsequent use to get volatile oil.Aqueous solution and preceding twice water cooking liquid 3. merge, and residue joins in second residue 3. and merges.
2. get Radix Bupleuri, Radix Paeoniae Rubra, Radix Scrophulariae and pulverize, with the ethanol extraction of 50%-90% 2-4 time,, be 0.5-3h at every turn, merging filtrate, recovery ethanol, concentrated, doubly measure 95% ethanol precipitation with 2-5.Filter, residue discards, and filtrating is recycled to the thick paste shape, and dries in the baking oven, grinds.
3. get Radix Ginseng, the Radix Rehmanniae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae and pulverize, add water 5-12 and doubly measure and boil 2-4 time, each 0.5-3h merges, and filters, concentrated thick paste shape.
4. get Cornu Cervi Pantotrichum, Colla Plastri Testudinis pulverizing, cross 80 mesh sieves.
5. with the above-mentioned thick paste that obtains, powder and Colla Plastri Testudinis powder fully mix, and dry in the baking oven, take out, and add the above-mentioned volatile oil that obtains, mixing.
6. process required preparation type by preparation process, like powder, capsule, pill etc.
Consumption usage: 2～3 times/day 5～10g/ time;
Indication: by the hypoproteinemia that hepar damnification caused;
The side separates: the present invention starts with strongly invigorating primordial QI, is monarch with Radix Ginseng, Rhizoma Polygonati, focuses on to mend its elder generation deficiency of the day after tomorrow; With the Radix Rehmanniae, Colla Plastri Testudinis, Radix Scrophulariae, Radix Paeoniae Rubra, Cornu Cervi Pantotrichum, Radix Angelicae Sinensis, Rhizoma Chuanxiong is minister, gets its nourishing YIN for suppressing the hyperactive YANG, the merit of liver heat removing and kidney replenishing, and hemopoietic, removing heat from blood and the usefulness of invigorating blood circulation, the front and back coordination of YIN and YANG is taken good care of Liver and kidney; With the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae is assistant, nourishing stomach and spleen, the absorption fortuneization of enhancing essence of water and grain; With Rhizoma Cyperi, Radix Bupleuri for making, circulation of qi promoting and in, harmonizing the functional activities of vital QI, poker water channel.
Through clinical observation for many years, by the hypoproteinemia that hepar damnification caused, no matter its origin cause of formation or present situation all come from the relevant etiology and pathology of following Chinese medicine.The one, insufficiency of primordial QI, function goes down; The 2nd, internal organs pent-up causes qi depression to blood stasis; The 3rd, spleen loses fortuneization, and the defeated cloth of the precise and tiny absorption day after tomorrow reduces.
Below test shows that pharmaceutical preparation of the present invention has obvious curative effects to the hypoproteinemia card that hepar damnification caused:
Seminar sets up rat experiment property Liver Fibrosis Model through subcutaneous injection CCL4 peanut oil solution; Observed the ginseng Testudinis and protected the liver of the influence of the white ball of liter experimental hepatic fibrosis rats serum albumin, liver function, hepatic tissue collagen and oxidative damage; Draw as drawing a conclusion: 1. all can obviously raise hepatic fibrosis rats serum ALB content and A/G ratio of preparation A and preparation B; Significantly reduce serum GLO content, point out it to synthesize, especially increase albuminous synthetic through promoting that hepatic tissue is proteinic; Correct low albumin and the inversion of Archon ratio that hepatic fibrosis causes, liver function is had a better role; 2. preparation A and preparation B all can obviously reduce serum AST and ALT vigor, reduce the generation of Hyp in the hepatic tissue, but point out its transaminase lowering, improve liver function, suppress a large amount of generations and the abnormal deposition of liver collagen fiber; 3. preparation A and preparation B all can obviously reduce MDA content in the hepatic tissue, significantly increased SOD activity and GSH content.Point out it possibly pass through to reduce lipid peroxidation, enhancing body is removed the oxygen-derived free radicals ability, alleviates the hepatocyte lipid peroxidation injury, alleviates hepatic necrosis, and hepatic tissue is had better antioxidation; 4. preparation A and preparation B all can reduce liver NO S activity and serum NO levels, and present certain dose-dependence.It is active and reduce serum NO levels to point out it can suppress liver NO S, the liver microcirculation that has some improvement, and the effect that alleviates the hepatic tissue radical damage, this has the certain significance to anti-hepatic fibrosis.
Acute toxicity test can't be obtained LD50, shows that this poison of drug property is low, and safety range is big.If develop, develop new drug, with breaking through the bottleneck that human albumin market lacks, for numerous hepatopaths bring glad tidings with complete independent intellectual property right by low Chinese medicine 6 kind new medicines of treatment cirrhotic ascites conalbumin.
Preparation A and preparation B are to the protective effect of experimental hepatic injury rat hypoproteinemia card
1 experiment material
1.1 the healthy Wistar rat of laboratory animal, male, body weight 180～220g is provided by preclinical medicine institute of Jilin University zoopery center, the certification of fitness number: SCXK-(Ji) 2007-0003.
1.2 medicine and reagent A side and B side provide (referring to embodiment 1 and embodiment 4), lot number: 20090215 by Chemical College, Jilin Univ. Natural Medicine Chemistry research department; The Malotilate sheet provides lot number by Jinzhou nonapeptide pharmaceutcal corporation, Ltd: 20090220; Produce lot number by the Beijing Chemical Plant by carbon tetrachloride: 20080106; Oleum Arachidis hypogaeae semen spends Group Co.,Ltd to produce lot number: 20081005 by a Qingdao Hu Ji; Albumin, protein quantification (Coomassie brilliant blue), alanine aminotransferase, aspartate transaminase, STB, acetylcholine esterase, superoxide dismutase, malonaldehyde, reduced glutathion-S transferring enzyme and hydroxyproline testing cassete build up bio-engineering research by Nanjing provides lot number: 20091012.
2 experimental techniques
2.1 animal divides into groups and modelling
1) with 200 male Wistar rats, as matched group, all the other 180 all as the modeling group by 20 of body weight picked at random, duplicates rat experiment property Liver Fibrosis Model.
2) rat experiment property Liver Fibrosis Model method for preparing is following: subcutaneous injection (sc) 40%CCl first 4Peanut oil solution 5ml/kg; Since equal sc 40%CCl on the 3rd 4Peanut oil solution 3ml/kg, per 3 days once, normal diet drinking-water.Control rats is the pure peanut oil solution 5ml/kg of sc first; Since the pure peanut oil solution 3ml/kg of equal sc on the 3rd, per 3 days once, normal diet drinking-water.
3) after the 18th modeling, tail vein blood is measured the rat blood serum albumin content.According to the serum albumin level and combine rat body weight, the modeling rat is divided into 8 groups at random then: model group, A side is little, in, heavy dose of group, B side is little, in, heavy dose of group and positive drug Malotilate group.
2.2 dosage regimen
1) matched group: irritate stomach and give 0.5% sodium carboxymethyl cellulose 10ml/kg
2) model group: irritate stomach and give 0.5% sodium carboxymethyl cellulose 10ml/kg
3) A side's small dose group: irritate stomach and give A side 1g/kg
4) dose groups in the A side: irritate stomach and give A side 2g/kg
5) the heavy dose of group in A side: irritate stomach and give A side 4g/kg
6) B side's small dose group: irritate stomach and give B side 1g/kg
7) dose groups in the B side: irritate stomach and give B side 2g/kg
8) the heavy dose of group in B side: irritate stomach and give B side 4g/kg
9) positive drug group: irritate stomach and give Malotilate sheet 0.1g/kg
Every morning 8:00～9:00 gastric infusion 1 time continued for 5 weeks altogether.During administration, model group, A side is little, in, heavy dose of group, B side is little, in, heavy dose of group and positive drug Malotilate group rat continue to keep Liver Fibrosis Model by above-mentioned modeling method, finish up to experiment.
2.3 blood sample and histioid collection and preparation
Killed Mus preceding 12 hours, water is can't help in the animal fasting.When killing Mus with animal with 10% chloral hydrate solution (300mg/kg) intraperitoneal injection of anesthesia, dispose as follows:
1) ventral aorta blood sampling, standing separation serum.Measure serum albumin (ALB), total protein (TP), bilirubin (BIL) content and acetylcholine esterase (CHE), alanine aminotransferase (ALT) and aspartate transaminase (AST) activity by the test kit requirement.
2) get liver, weigh, calculate liver coefficient (liver weight/body weight * 100) according to body weight.
3) get the part hepatic tissue, preparation homogenate.Measure hepatic tissue superoxide dismutase (SOD) and glutathion-S transferring enzyme (GSH-ST) activity, malonaldehyde (MDA) and histone content by the test kit requirement.
4) measure serum and organize total protein (TP) content by Coomassie brilliant blue testing cassete method.Deduct serum ALB content with serum T P content and get serum globulin (GLO) content.
5) get the 200mg hepatic tissue and prepare homogenate, measure hepatic tissue hydroxyproline (Hyp) content by the test kit requirement.
2.4 statistical method
Experimental data adopts group difference comparison Student-t check carrying out statistical analysis with means standard deviation
Figure GSA00000133302500051
expression.
3 experimental results
3.1 liver coefficient and matched group are relatively, model group rat liver coefficient significantly increases (P＜0.01); With model group relatively, in the A side, heavy dose of group, B side is little, in, heavy dose of group and positive drug Malotilate group all can reduce liver coefficient (P＜0.05 or P＜0.01) by significance, sees table 1.
Table 1A side and B side are to the influence (
Figure GSA00000133302500052
n=10) of experimental hepatic fibrosis rats liver coefficient
Figure GSA00000133302500053
Compare with matched group ##P＜0.01; Compare with model group *P＜0.05, *P＜0.01
3.2 serum albumin (ALB) compares with matched group, model group rat blood serum ALB content significantly reduces (P＜0.001).With model group relatively, in the A side, heavy dose of group and B side is little, in, heavy dose of group all has rising effect (P＜0.05～P＜0.001) in various degree to serum ALB content, the positive drug Malotilate serum ALB content (P＜0.05) that also can significantly raise; In heavy dose of group in A side and the B side, heavy dose of group obviously is superior to positive drug Malotilate group (P＜0.05) to the rising effect of serum ALB content, sees table 2.
3.3 serum globulin (GLO) is compared with matched group, model group rat blood serum GLO content significantly raise (P＜0.01).With model group relatively, in heavy dose of group in A side and the B side, heavy dose of group all can significantly reduce rat blood serum GLO content (P＜0.05), positive drug Malotilate group does not have obvious influence (P＞0.05) to rat blood serum GLO content, sees table 2.
3.4 total serum protein (TP) is compared with matched group, model group rat blood serum TP content decreases, but difference not significantly (P＞0.05).Compare with model group, A side, B side and positive drug Malotilate group all have rising effect in various degree to serum T P content, but do not have significant difference (P＞0.05), see table 2.
3.5 serum albumin/globulin (A/G) is compared with matched group, model group rat A/G ratio significantly reduces (P＜0.01).With model group relatively, in the A side, heavy dose of group, B side is little, in, heavy dose of group A/G ratio (P＜0.05 or P＜0.01) that all significantly raises, in the B side, heavy dose of group obviously is superior to positive drug Malotilate group (P＜0.05) to the rising effect of A/G ratio, sees table 2.
Table 2A side and B side are to the influence (
Figure GSA00000133302500061
n=10) of experimental hepatic fibrosis rats serum ALB, GLO, TP and A/G
Figure GSA00000133302500062
Compare with matched group ##P＜0.01, ###P＜0.001
Compare with model group *P＜0.05, *P＜0.01, * *P＜0.001
Compare with the Malotilate group ΔP＜0.05
3.6 serum transaminase (ALT and AST) compares with matched group, model group rat blood serum ALT and AST activity be significantly rising (P＜0.001) all.With model group relatively, in the A side, heavy dose of group, B side is little, in, heavy dose of group and positive drug Malotilate group all can significantly reduce Serum ALT and AST active (P＜0.05 or P＜0.01), no significant difference between the three (P＞0.05) is seen table 3.
Table 3A side and B side are to the influence (
Figure GSA00000133302500063
n=10) of experimental hepatic fibrosis rats Serum ALT and AST
Compare with matched group ###P＜0.001
Compare with model group *P＜0.05, *P＜0.01
3.7 serum cholinesterase (CHE) and bilirubin (BIL) and matched group are relatively, model group rat blood serum CHE is active significantly to raise, BIL content significantly descend (P＜0.05 or P＜0.01).With model group relatively, in A side and the B side, that heavy dose of group and positive drug Malotilate group all can significantly reduce change of serum C HE is active, and the serum BIL content (P＜0.05) that significantly raises, no significant difference between the three (P＞0.05) is seen table 4.
Table 4A side and B side are to the influence (
Figure GSA00000133302500072
n=10) of experimental hepatic fibrosis rats change of serum C HE and BIL
Figure GSA00000133302500073
Compare with matched group #P＜0.05, ##P＜0.01; Compare with model group *P＜0.05
3.8 hepatic tissue MDA, SOD, GSH-ST and Hyp and matched group are relatively, model group liver tissues of rats SOD and GSH-ST activity all obviously reduce (P＜0.05 or P＜0.01), and MDA and Hyp content is obviously rising (P＜0.01) all.Compare with model group; In A side and the B side, heavy dose of group and positive drug Malotilate group all significantly increased SOD and GSH-ST active (P＜0.05 or P＜0.01); Obviously reduce MDA and Hyp content (P＜0.05 or P＜0.01), no significant difference between the three (P＞0.05) is seen table 5.
Table 5A side and B side are to the influence (
Figure GSA00000133302500081
n=10) of experimental hepatic fibrosis rats hepatic tissue MDA, SOD, GSH-ST and Hyp
Figure GSA00000133302500082
Compare with matched group #P＜0.05, ##P＜0.01; Compare with model group *P＜0.05, *P＜0.01
The good effect of medicine of the present invention is: be made up of the pure Chinese medicine of 13 flavors such as Radix Ginseng and Colla Plastri Testudinis, its effect is the liver soothing and the spleen invigorating, activating blood circulation to dissipate blood stasis, and hard masses softening and resolving is taken a tonic or nourishing food to build up one's health healthy energy.For the low patient of cirrhotic ascites conalbumin, can not only eliminate ascites, the plasma albumin that can also obviously raise, integrally-regulated health internal organs function is not attended to one thing and lose sight of another, and can take for a long time, has no side effect.
The specific embodiment
For the ease of understanding the present invention, special case is lifted following examples.Its effect is understood that it is to explaination of the present invention but not to any type of restriction of the present invention.
Embodiment 1:
Preparation A: Radix Ginseng 30g, Rhizoma Polygonati 30g, Radix Rehmanniae 15g, Radix Angelicae Sinensis 15g, Radix Scrophulariae 15g, Colla Plastri Testudinis 15g, Rhizoma Chuanxiong 15g, Rhizoma Atractylodis Macrocephalae 15g, Radix Bupleuri 20g.
Method for making: 1. get Rhizoma Chuanxiong, Radix Angelicae Sinensis pulverizing, the three is mixed, soak 2h, vapor distillation, heating extraction 10h, extraction gets volatile oil, and is subsequent use.Aqueous solution and preceding twice water cooking liquid 3. merge, and residue joins in second residue 3. and merges, and decocting in water (the 3rd time) filters merging filtrate.
2. get Radix Bupleuri, Radix Scrophulariae pulverizing, the ethanol extraction with 60% 3 times is 2h for the first time, is 2h for the second time, is 1h for the third time, and merging filtrate reclaims ethanol, concentrates, and measures 95% ethanol precipitations with 5 times.Filter, residue discards, and filtrating is recycled to the thick paste shape, and dries in the baking oven, grinds.
3. getting Radix Ginseng, the Radix Rehmanniae, Rhizoma Polygonati, Rhizoma Atractylodis Macrocephalae pulverizing, add 8 times of amounts of water and boil 3 times, is 2.5h for the first time, is 2h for the second time, is 1.5h for the third time, merges, and filters concentrated thick paste shape.
4. get Colla Plastri Testudinis and pulverize, cross 80 mesh sieves.
5. with the above-mentioned thick paste that obtains, powder and Colla Plastri Testudinis powder fully mix, and dry in the baking oven, take out, and add the above-mentioned volatile oil that obtains, mixing.
6. oven dry is once more taken out, put cold, bottling or become bag, the sealing of sterilization back.
Character: these article are the brownish red powder, mildly bitter flavor, oils and fats.
Embodiment 2:
Preparation A: Radix Ginseng 30g, Rhizoma Polygonati 20g, Radix Rehmanniae 15g, Radix Angelicae Sinensis 15g, Radix Scrophulariae 10g, Colla Plastri Testudinis 10g, Rhizoma Chuanxiong 15g, Rhizoma Atractylodis Macrocephalae 20g, Radix Bupleuri 15g.
Method for preparing 1. 2. 3. 4. 5. step 6. add alcohol dampening with embodiment 1, make the watered pill.Character: these article are the brownish red pill.
Embodiment 3:
Preparation A: Radix Ginseng 30g, Rhizoma Polygonati 30g, Radix Rehmanniae 30g, Radix Angelicae Sinensis 20g, Radix Scrophulariae 10g, Colla Plastri Testudinis 10g, Rhizoma Chuanxiong 20g, Rhizoma Atractylodis Macrocephalae 20g, Radix Bupleuri 5g.Method for preparing 1. 2. 3. 4. 5. step 6. add an amount of dextrin with embodiment 1, granulate the dress capsule.Every 0.3g.
Embodiment 4
Preparation B: Radix Ginseng 30g, Rhizoma Polygonati 30g, Radix Rehmanniae 15g, Radix Angelicae Sinensis 15g, Radix Scrophulariae 15g, Colla Plastri Testudinis 15g, Rhizoma Chuanxiong 15g, Rhizoma Atractylodis Macrocephalae 15g, Radix Bupleuri 20g, Cornu Cervi Pantotrichum 5g, Radix Paeoniae Rubra 15g, Radix Glycyrrhizae 15g, Rhizoma Cyperi 15g.
Method for making: 1. get Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Cyperi pulverizing, the three is mixed, soak 2h, vapor distillation, heating extraction 10h, extraction gets volatile oil, and is subsequent use.Aqueous solution and preceding twice water cooking liquid 3. merge, and residue joins in second residue 3. and merges, and decocting in water (the 3rd time) filters merging filtrate.
2. get Radix Bupleuri, Radix Paeoniae Rubra, Radix Scrophulariae pulverizing, the ethanol extraction with 60% 3 times is 2h for the first time, is 2h for the second time, is 1h for the third time, and merging filtrate reclaims ethanol, concentrates, and measures 95% ethanol precipitations with 5 times.Filter, residue discards, and filtrating is recycled to the thick paste shape, and dries in the baking oven, grinds.
3. getting Radix Ginseng, the Radix Rehmanniae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae pulverizing, add 8 times of amounts of water and boil 3 times, is 2.5h for the first time, is 2h for the second time, is 1.5h for the third time, merges, and filters concentrated thick paste shape.
4. get Cornu Cervi Pantotrichum, Colla Plastri Testudinis pulverizing, cross 80 mesh sieves.
With the above-mentioned thick paste that obtains, powder and Cornu Cervi Pantotrichum and Colla Plastri Testudinis powder fully mix, and dry in the baking oven, take out, and add the above-mentioned volatile oil that obtains, mixing.
6. oven dry is once more taken out, put cold, bottling or become bag, the sealing of sterilization back.Character: these article are the brownish red powder, mildly bitter flavor, oils and fats.
Embodiment 5:
Radix Ginseng 30g, Rhizoma Polygonati 20g, Radix Rehmanniae 15g, Radix Angelicae Sinensis 15g, Radix Scrophulariae 10g, Colla Plastri Testudinis 10g, Rhizoma Chuanxiong 15g, Rhizoma Atractylodis Macrocephalae 20g, Radix Bupleuri 15g, Cornu Cervi Pantotrichum 10g, Radix Paeoniae Rubra 10g, Radix Glycyrrhizae 5g, Rhizoma Cyperi 15g.Method for preparing 1. 2. 3. 4. 5. step 6. add alcohol dampening with embodiment 4, make the watered pill.Character: these article are the brownish red pill
Embodiment 6:
Radix Ginseng 30g, Rhizoma Polygonati 30g, Radix Rehmanniae 30g, Radix Angelicae Sinensis 20g, Radix Scrophulariae 10g, Colla Plastri Testudinis 10g, Rhizoma Chuanxiong 20g, Rhizoma Atractylodis Macrocephalae 20g, Radix Bupleuri 5g, Cornu Cervi Pantotrichum 5g, Radix Paeoniae Rubra 15g, Radix Glycyrrhizae 5g, Rhizoma Cyperi 20g.Method for preparing 1. 2. 3. 4. 5. with embodiment 4.6. add an amount of dextrin, granulate, the dress capsule.Every 0.3g.

Claims (4)

  1. A treatment since the Chinese medicine preparation of the hypoproteinemia card that hepar damnification caused it is characterized in that by comprising what the following portions by weight proportion raw material was processed:
    5～30 parts of Radix Ginsengs, 5～30 parts of Rhizoma Polygonatis, 5～30 parts in the Radix Rehmanniae, 5～30 parts of Radix Angelicae Sinensis, 5～30 parts of Radix Scrophulariaes, 5～30 parts of Colla Plastri Testudinises, 5～30 parts of Rhizoma Chuanxiongs, 5～30 parts of the Rhizoma Atractylodis Macrocephalaes, 5～30 parts of Radix Bupleuri.
  2. 2. Chinese medicine preparation according to claim 1 is characterized in that: processed by raw material in the claim 1 and following portions by weight proportion raw material:
    5～30 parts in Cornu Cervi Pantotrichum, 5～30 parts of Radix Paeoniae Rubra, 5～30 parts in Radix Glycyrrhizae, 5～30 parts of Rhizoma Cyperis.
  3. 3. according to the concrete method for preparing of the said Chinese medicine preparation of claim 1, comprise the steps:
    1. get Rhizoma Chuanxiong, Radix Angelicae Sinensis pulverizing, both are mixed, soak 1-6h, vapor distillation, heating extraction 5-15h, extraction, it is subsequent use to get volatile oil; Aqueous solution and preceding twice water cooking liquid 3. merge, and merge in the decocting in water residue second time that 3. residue joins;
    2. get Radix Bupleuri, Radix Scrophulariae and pulverize, with the ethanol extraction of 50%-90% 2-4 time, be 0.5-3h at every turn, merging filtrate, and recovery ethanol, concentrated, doubly measure 95% ethanol precipitation with 2-5; Filter, residue discards, and filtrating is recycled to the thick paste shape, and dries in the baking oven, grinds;
    3. get Radix Ginseng, the Radix Rehmanniae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae and pulverize, add water 5-12 and doubly measure and boil 2-4 time, each 0.5-3h merges, and filters, concentrated thick paste shape;
    4. get Colla Plastri Testudinis and pulverize, cross 80 mesh sieves;
    5. with the above-mentioned thick paste that obtains, powder and Colla Plastri Testudinis powder fully mix, and dry in the baking oven, take out, and add the above-mentioned volatile oil that obtains, mixing;
    6. process required preparation type by preparation process.
  4. 4. according to the concrete method for preparing of the said Chinese medicine preparation of claim 2, comprise the steps:
    1. get Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Cyperi pulverizing, the three is mixed, soak 1-6h, vapor distillation, heating extraction 5-15h, extraction, it is subsequent use to get volatile oil; Aqueous solution and preceding twice water cooking liquid 3. merge, and merge in the decocting in water residue second time that 3. residue joins;
    2. get Radix Bupleuri, Radix Paeoniae Rubra, Radix Scrophulariae and pulverize, with the ethanol extraction of 50%-90% 2-4 time, be 0.5-3h at every turn, merging filtrate, and recovery ethanol, concentrated, doubly measure 95% ethanol precipitation with 2-5; Filter, residue discards, and filtrating is recycled to the thick paste shape, and dries in the baking oven, grinds;
    3. get Radix Ginseng, the Radix Rehmanniae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae and pulverize, add water 5-12 and doubly measure and boil 2-4 time, each 0.5-3h merges, and filters, concentrated thick paste shape;
    4. get Cornu Cervi Pantotrichum, Colla Plastri Testudinis pulverizing, cross 80 mesh sieves;
    5. with the above-mentioned thick paste that obtains, powder and Colla Plastri Testudinis powder fully mix, and dry in the baking oven, take out, and add the above-mentioned volatile oil that obtains, mixing;
    6. process required preparation type by preparation process.
CN2010101787035A 2010-05-21 2010-05-21 Chinese medicinal preparation for treating hypoproteinemia caused by liver damage Expired - Fee Related CN101884730B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010101787035A CN101884730B (en) 2010-05-21 2010-05-21 Chinese medicinal preparation for treating hypoproteinemia caused by liver damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101787035A CN101884730B (en) 2010-05-21 2010-05-21 Chinese medicinal preparation for treating hypoproteinemia caused by liver damage

Publications (2)

Publication Number Publication Date
CN101884730A CN101884730A (en) 2010-11-17
CN101884730B true CN101884730B (en) 2012-07-25

Family

ID=43070930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010101787035A Expired - Fee Related CN101884730B (en) 2010-05-21 2010-05-21 Chinese medicinal preparation for treating hypoproteinemia caused by liver damage

Country Status (1)

Country Link
CN (1) CN101884730B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104524086B (en) * 2014-12-09 2018-02-16 青岛农业大学 A kind of Chinese medicine composition for being used to treat Cynoglossus semilaevis Ascites Disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063076C (en) * 1997-12-09 2001-03-14 郭振昌 Traditional Chinese medicinal leukogenic prepn.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063076C (en) * 1997-12-09 2001-03-14 郭振昌 Traditional Chinese medicinal leukogenic prepn.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
朱先女等.软肝升白汤对乙型肝炎肝硬化患者瘦素_胰岛素_省略_长因子_1_生长激素_血清白蛋.《中西医结合肝病杂志》.2008,第18卷(第3期),134-136. *
胡尚久.升白护肝口服液的制备及质量控制.《中国医院药学杂志》.2003,第23卷(第2期),117-118. *

Also Published As

Publication number Publication date
CN101884730A (en) 2010-11-17

Similar Documents

Publication Publication Date Title
CN103990081B (en) Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice
CN103316324B (en) Traditional Chinese medicine foot-bathing liquid for treating rheumatoid disease
CN103719498A (en) Immunity-enhancing sealwort health-care tea and preparation method thereof
CN103301440B (en) Chinese medicine capable of warming Yang and tonifying kidneys
CN104338043B (en) A kind of medicine for improving immunity and preparation method thereof
CN106617000A (en) Traditional Chinese medicinal composition for enhancing immunity and relieving fatigue, as well as preparation method and application of traditional Chinese medicinal composition
CN103301413A (en) Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia
CN102973660B (en) Chronic hepatitis treatment traditional Chinese medicine composition and preparation method thereof
CN103223131B (en) Liver disease drug
CN102048902B (en) Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation
CN103316305A (en) Traditional Chinese medicine composition for treating liver cirrhosis and preparation method thereof
CN102847061B (en) Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof
CN101112533A (en) Chinese traditional medicine composition for treating and preventing gout and method of making the same
CN101884730B (en) Chinese medicinal preparation for treating hypoproteinemia caused by liver damage
CN101167872B (en) Medicinal composition for beautifying and face-nourishing and preparation method thereof
CN106334171A (en) Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof
CN102949659A (en) Traditional Chinese medicine composition for treating hepatitis B
CN104147277A (en) Traditional Chinese medicinal preparation for treating myasthenia gravis and preparation method
CN114272349A (en) Traditional Chinese medicine composition for tonifying spleen and nourishing liver and preparation method and application thereof
CN103505500B (en) A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof
CN103007171B (en) Traditional Chinese medicine composition for curing remitted schizophrenia and preparing method of traditional Chinese medicine composition
CN1876062A (en) Preparation method of traditional Chinese medicine for treating hepatitis B and liver cirrhosis and Chinese medicine prepared thereby
CN105853697A (en) Traditional Chinese medicine preparation for treating infantile fevers and preparation method thereof
CN104758539A (en) Traditional Chinese medicine composition for treating debilitation
CN105770188B (en) liver-protecting traditional Chinese medicine preparation and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120725

Termination date: 20150521

EXPY Termination of patent right or utility model